NCT07217496 2026-03-17
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
Phase 1 Withdrawn
University of California, San Francisco
Dana-Farber Cancer Institute
University of Utah
ImmunityBio, Inc.
Altor BioScience
Altor BioScience
Case Comprehensive Cancer Center
Altor BioScience